GYRE THERAPEUTICS INC

Gyre Therapeutics insider buys at $0.75 amid a $3.7M preferred‑stock raise, signaling confidence in F351’s progress—could spark a rally despite dilution risks.

Gyre Therapeutics’ COO Ye Weiguo’s recent net‑buying signals insider confidence in the F351 program, offering investors a subtle cue amid volatile stock dynamics.

CEO Luo Ying’s recent Gyre Therapeutics stock sales are pre‑planned, not a crisis signal – investors should weigh the company’s biotech strategy and upcoming milestones before reacting.

Gyre Therapeutics’ insider filings reveal CEO Luo Ying’s 2.5M+ share options, senior exec buying, and high social buzz—indicating long‑term confidence and a potential upside ahead of hydronidone trial data.